Work

Health Outcomes and Hormone Therapy Source in Transgender Adults

Year: 2025

Type: article

Abstract: Gender-affirming hormone therapy (GAHT), the administration of sex hormones to affirm one’s gender identity, is one of the most desired gender-affirming interventions among transgender and gender-diverse (TGD) individuals.1,2 Like hormone replacement therapy in cisgender individuals, GAHT may carry long-term health risks.3 As access becomes increasingly restricted, some TGD individuals may turn to unlicensed sources for hormone therapy, further increasing potential risks. Limited data exist on medical comorbidities among TGD adults receiving GAHT.

Source: American Journal of Preventive Medicine

DOI: 10.1016/j.amepre.2025.107657

Authors: Rishub K. Das, Brian C. Drolet

Institution: Vanderbilt University Medical Center

Language: English

Topic: LGBTQ Health, Identity, and Policy

Subfield: Social Psychology

Field: Psychology

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,300